Evidence map›Paper›PMID 40895900›Full record

ArticleCureus2025

Synthetic Drug Use and Limitations of Hospital Drug Screening: A Case of Gamma-Hydroxybutyrate Toxicity.

Lily D Rundquist, Emma Newquist, Erick A Boldt, Daniel Pacciulli, Victoria Echevarria, Tianna L Nelson, Azjaah Rogers, Rebecca Cherner

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lily D RundquistDr. Kiran C. Patel College of Osteopathic Medicine (KPCOM), Nova Southeastern University, Fort Lauderdale, USA.
Emma NewquistDr. Kiran C. Patel College of Osteopathic Medicine (KPCOM), Nova Southeastern University, Fort Lauderdale, USA.
Erick A BoldtDr. Kiran C. Patel College of Osteopathic Medicine (KPCOM), Nova Southeastern University, Fort Lauderdale, USA.
Daniel PacciulliFamily Medicine, Broward Health Medical Center, Fort Lauderdale, USA.
Victoria EchevarriaFamily Medicine, Broward Health Medical Center, Fort Lauderdale, USA.
Tianna L NelsonFamily Medicine, Broward Health Medical Center, Fort Lauderdale, USA.
Azjaah RogersFamily Medicine, Broward Health Medical Center, Fort Lauderdale, USA.
Rebecca ChernerFamily Medicine, Broward Health Medical Center, Fort Lauderdale, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gamma-hydroxybutyrate (GHB) is a drug that acts as a central nervous system depressant and is commonly known to be used recreationally. We present the case of a 31-year-old male patient with a past medical history of hypertension (HTN), polysubstance abuse, and previous fentanyl overdose who was brought in an unconscious state to the emergency department (ED) after a suspected GHB overdose. Upon arrival at the ED, the patient was obtunded and therefore medically sedated and intubated for airway protection. His initial laboratory workup revealed a negative serum drug screen and positive urine drug screen for methamphetamines. Both urinalysis and respiratory panel were unremarkable. Several hours later, the patient regained consciousness, became agitated, and self-extubated. The patient's presentation of altered mental status, respiratory depression, and subsequent agitation was attributed to the GHB overdose; however, due to limitations on standard hospital drug screens, it was not detected on the initial work-up. This case aims to demonstrate the increase in the prevalence of GHB use and the importance of considering it in the differential diagnosis of suspected overdose patients. In addition, this case highlights the need for broader toxicology reports in hospital settings to improve the timely diagnosis and management of GHB-related overdoses.

Indexed as

drug overdosedrug overdose managementgamma-hydroxybutyratenatural and synthetic illicit drugsurine drug screen limitations

Identifiers

PMID40895900
PMCPMC12392695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.